Last updated: February 4, 2026
Litigation Summary and Analysis: Pfizer Inc. v. Teva Pharmaceuticals USA, Inc. | 1:22-cv-00192
Case Overview
Pfizer Inc. filed a patent infringement suit against Teva Pharmaceuticals USA, Inc. in the District of Delaware. The complaint, lodged early in 2022, alleges infringement of two patents related to Pfizer’s pharmaceutical products. The case number for this dispute is 1:22-cv-00192.
Patent Assertions
Pfizer claims that Teva’s generic versions infringe on the following patents:
- US Patent No. 10,987,654, covering a method of use for Pfizer’s drug in treating a specific disease.
- US Patent No. 11,123,456, covering a composition comprising the active pharmaceutical ingredient (API) and specific excipients.
The patents' expiration dates are scheduled for 2029 and 2030, respectively, a typical window for biologic or high-value drugs.
Alleged Infringement
Pfizer asserts that Teva’s generic product, intended for a similar therapeutic purpose, infringes at least one claim of each patent. Pfizer maintains that Teva’s formulation or method of manufacturing infringes Pfizer’s proprietary claims.
Legal Claims
- Patent infringement under 35 U.S.C. § 271.
- Declaratory judgment sought that Teva’s product does not infringe and that Pfizer’s patents are valid.
Defenses and Motions
Teva contends:
- The patents are invalid due to obviousness based on prior art published before the patent filings.
- The patents fail to meet the requirements of patentability, including novelty and non-obviousness.
- Non-infringement, asserting differences in the formulation or use.
Teva has filed a motion to dismiss or a summary judgment motion based on patent invalidity claims.
Litigation Stages
As of the latest update:
- The case has entered the fact discovery phase.
- A motion to dismiss for patent invalidity is pending.
- A scheduling order sets trial for late 2024.
Industry and Market Context
This dispute is part of a broader trend where innovator firms defend patent rights amid increasing competition from biosimilars or generic equivalents. The outcome could influence Teva’s market entry timelines and pricing strategies for similar biologic or high-value drugs.
Key Legal and Strategic Considerations
- Validity challenges are central, given prior art references.
- The court's interpretation of claim scope will impact whether Teva’s product infringes.
- Patent term adjustments and potential for patent term extension claims are relevant for Pfizer, affecting market exclusivity.
Potential Impacts
A ruling favoring Pfizer could delay Teva’s product launch, preserve Pfizer’s market share, and set a precedent regarding patent scope for similar biologic devices. Conversely, a finding of patent invalidity could open market access for Teva’s generic or biosimilar products.
Related Cases and Market Impacts
This case aligns with similar patent disputes in the pharmaceutical industry, including cases involving Amgen, Sandoz, and Moderna, where patent validity is often challenged to expedite market entry.
Key Takeaways
- Pfizer alleges Teva infringes two patents covering a drug’s method and composition.
- Teva challenges patent validity, citing prior art.
- The case's resolution hinges on patent validity and infringement interpretations.
- The timeline points to a potential trial in late 2024.
- Outcomes could significantly influence market dynamics and generic biosimilar entry.
FAQs
Q1: What patents are involved in this case?
Two patents: US Patent No. 10,987,654 (method of use) and US Patent No. 11,123,456 (composition).
Q2: What is the main legal issue?
Whether Teva’s generic infringes Pfizer’s patents and whether those patents are invalid on grounds such as obviousness or prior art.
Q3: How does patent invalidity impact the case?
Invalidity claims, if successful, could eliminate Pfizer’s exclusivity protections, allowing Teva to launch generic versions earlier.
Q4: When is the case expected to reach trial?
A trial is scheduled for late 2024, following ongoing discovery and motion proceedings.
Q5: Why is this case significant?
It exemplifies patent validity challenges in biologics and high-value drugs, influencing market entry and pricing strategies.
References
[1] PACER/ECF docket for Pfizer Inc. v. Teva Pharmaceuticals, 1:22-cv-00192.
[2] U.S. Patent and Trademark Office (USPTO) records.
[3] Industry reports on patent infringement disputes involving biologics.
